CD19 and acute lymphoblastic leukemia: The current work goes deeper into the cellular kinetics and factors impacting expansion, persistence, and response of this genome-edited allogeneic anti-CD19 CAR-T cell therapy administered to 25 non–HLA-matched adult patients with R/R B-ALL as part of the CALM clinical trial.